title: Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: Possible mechanism of action.
authors.affiliation: University of São Paulo (USP), School of Odontology of Ribeirão Preto, Department of Morphology, Physiology and Basic Pathology, Av. Café S/N, 14040-904 Ribeirão Preto, SP, Brazil; USP, Center for Interdisciplinary Research on Applied Neurosciences (NAPNA), Brazil; USP, Medical School of Ribeirão Preto, Department of Physiology, Av. Bandeirantes 3900, 14049-900 Ribeirão Preto, SP, Brazil.
authors.forename: Maurício
authors.initials: M
authors.lastname: Dos-Santos-Pereira
authors.affiliation: University of São Paulo (USP), School of Odontology of Ribeirão Preto, Department of Morphology, Physiology and Basic Pathology, Av. Café S/N, 14040-904 Ribeirão Preto, SP, Brazil; USP, Center for Interdisciplinary Research on Applied Neurosciences (NAPNA), Brazil.
authors.forename: Célia Aparecida
authors.initials: CA
authors.lastname: da-Silva
authors.affiliation: USP, Center for Interdisciplinary Research on Applied Neurosciences (NAPNA), Brazil; USP, Medical School of Ribeirão Preto, Department of Pharmacology, Av. Bandeirantes 3900, 14049-900 Ribeirão Preto, SP, Brazil.
authors.forename: Francisco Silveira
authors.initials: FS
authors.lastname: Guimarães
authors.affiliation: University of São Paulo (USP), School of Odontology of Ribeirão Preto, Department of Morphology, Physiology and Basic Pathology, Av. Café S/N, 14040-904 Ribeirão Preto, SP, Brazil; USP, Center for Interdisciplinary Research on Applied Neurosciences (NAPNA), Brazil; USP, Medical School of Ribeirão Preto, Department of Physiology, Av. Bandeirantes 3900, 14049-900 Ribeirão Preto, SP, Brazil; USP, Medical School of Ribeirão Preto, Department of Pharmacology, Av. Bandeirantes 3900, 14049-900 Ribeirão Preto, SP, Brazil. Electronic address: eadelbel@forp.usp.br.
authors.forename: Elaine
authors.initials: E
authors.lastname: Del-Bel
mesh_terms: D000818:Animals; D018726:Anti-Dyskinesia Agents / Q000494:pharmacology* / Q000633:toxicity*; D001095:Arachidonic Acids / Q000378:metabolism; D001921:Brain / Q000187:drug effects / Q000473:pathology; D002185:Cannabidiol / Q000494:pharmacology*; D002211:Capsaicin / Q000031:analogs & derivatives* / Q000494:pharmacology; D051546:Cyclooxygenase 2 / Q000378:metabolism; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D063388:Endocannabinoids / Q000378:metabolism; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D006657:Histones / Q000378:metabolism; D007980:Levodopa / Q000633:toxicity*; D008297:Male; D008810:Mice, Inbred C57BL; D016328:NF-kappa B / Q000378:metabolism; D016627:Oxidopamine; D047495:PPAR gamma / Q000378:metabolism; D020734:Parkinsonian Disorders / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D053284:Polyunsaturated Alkamides / Q000378:metabolism; D043884:Receptor, Cannabinoid, CB1 / Q000378:metabolism; D050916:TRPV Cation Channels / Q000378:metabolism; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
chemical_list: D018726:Anti-Dyskinesia Agents; D001095:Arachidonic Acids; C578453:CNR1 protein, mouse; D063388:Endocannabinoids; D006657:Histones; D016328:NF-kappa B; D047495:PPAR gamma; D053284:Polyunsaturated Alkamides; D043884:Receptor, Cannabinoid, CB1; D050916:TRPV Cation Channels; C493921:TRPV1 protein, mouse; D002185:Cannabidiol; D007980:Levodopa; D016627:Oxidopamine; D014446:Tyrosine 3-Monooxygenase; C077623:Ptgs2 protein, mouse; D051546:Cyclooxygenase 2; D048049:Extracellular Signal-Regulated MAP Kinases; C071423:capsazepine; D002211:Capsaicin; C078814:anandamide
keywords: AIMs; Anandamide; CB1; COX-2; Cannabinoid; ERK 1/2; LID; NF-κB; Neuroinflammation; PPAR gamma; TRPV-1; pAcH3